Completed PHASE2 INTERVENTIONAL 2-arm NCT00999167

A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy (HALT-HE)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of HPN-100 for Maintaining Remission in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy

Sponsor: Amgen

Conditions Cirrhosis Hepatic Encephalopathy

Interventions HPN-100 Placebo

Updated 8 times since 2017 Last updated: Jun 18, 2024 Started: Dec 31, 2009 Primary completion: Apr 30, 2012 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00999167, this PHASE2 trial focuses on Cirrhosis and Hepatic Encephalopathy and remains completed. Sponsored by Amgen, it has been updated 8 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Aug 2024 — Sep 2024 [monthly]

Completed PHASE2
Jul 2024 — Aug 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Charlottesville, United States , Chicago, United States , Cincinnati, United States , Cleveland, United States , Dallas, United States , Detroit, United States , Houston, United States , Indianapolis, United States , Iowa City, United States and 14 more locations